STAT

Can Roche’s little tech startup help the FDA change clinical trials?

A startup founded by two guys in their 20s turned into a $1.9 billion acquisition — and now is increasingly catching the interest of the FDA.

Could a startup founded by two guys in their 20s change the way medical researchers study patients? The Food and Drug Administration is open to the possibility.

Flatiron Health began as a small New York tech company trying to use real-world data from patient electronic medical records to replace more traditional clinical trial data. Then it raised $328 million, launched a modest collaboration with the FDA to study the use of its so-called “real-world” data in 2016, and entered partnerships with just about every major drug firm. Last year, it was acquired for $1.9 billion by the Swiss drug giant Roche Holding.

On Monday, Flatiron will announce that it is renewing and expanding its research relationship with the FDA, allowing the agency to further test

You're reading a preview, sign up to read more.

More from STAT

STAT2 min read
This Troubled Biotech Needed Cash, So It Turned To A Predatory Lender: Its Own CEO
I don’t write about Northwest Biotherapeutics much anymore because it’s not cool to punch down. However, there was a juicy nugget in the cancer biotech’s recently filed 10-Q that had to be shared. It’s another example of a biotech executive getting r
STAT7 min readPolitics
Trump Has Made A Priority Of Trying To Lower Drug Prices. But Many Of His Most Ardent Supporters Don’t Know It
Few of his supporters — even those willing to blast "Big Pharma" or whose ears perked up at the mention of drug importation — had any idea that Trump had…
STAT4 min readSociety
AIDS Activists Say Gilead Put Profits Over Patients — And Misled Congress About An HIV Pill
AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill.